{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"TEAE Related to P-BCMA-101"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"TEAE Not Related to P-BCMA-101"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Incidence and severity of treatment-emergent adverse events","groups":[{"description":"CAR-T cells administered via intravenous infusion as a total dose","id":"OG000","title":"Phase 2: P-BCMA-101 CAR-T Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Baseline through 24 months","title":"Phase 2: Assess the Safety of P-BCMA-101","type":"PRIMARY","unitOfMeasure":"Participants"}